<DOC>
	<DOCNO>NCT01901900</DOCNO>
	<brief_summary>This extension study provide continue treatment secukinumab 3 year subject complete phase III core study , CAIN457F2302 . Subjects offer maintenance treatment secukinumab 150 mg give subcutaneously every 4 week . The study aim obtain long term efficacy , safety tolerability information secukinumab patient rheumatoid arthritis .</brief_summary>
	<brief_title>Safety Efficacy Extended Treatment With Secukinumab Anti-TNF Inadequate Responders RA .</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Subjects must give write informed consent assessment perform . Subjects must complete 104week treatment period core study Subjects deem investigator benefit continue secukinumab therapy . Use investigational drug except secukinumab core study . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test . Women childbearing potential , defined woman physiologically capable become pregnant , unless use effective method contraception dose study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>moderate severe RA</keyword>
	<keyword>anti-TNF inadequate responder</keyword>
</DOC>